US Pharma MarketingGilead pledges 400K AmBiosome doses to fight visceral leishmaniasis in expanded WHO collab
Gilead Sciences and the World Health Organization (WHO) are doubling down on a pact to eliminate deadly parasitic disea Gilead’s five-year contract with the WHO is centered on providing AmBisome to countries that make up 74% of the global visceral leishmaniasis burden, according to the company.
Gilead’s five-year contract with the WHO is centered on providing AmBisome to countries that make up 74% of the global visceral leishmaniasis burden, according to the company.
Source: FiercePharma